0RIS Stock Overview
A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 11.20 |
| 52 Week High | NOK 37.20 |
| 52 Week Low | NOK 11.12 |
| Beta | 2.06 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -96.14% |
| 5 Year Change | -95.71% |
| Change since IPO | -96.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | -1.5% |
| 1Y | n/a | -21.4% | 3.5% |
Return vs Industry: Insufficient data to determine how 0RIS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0RIS performed against the UK Market.
Price Volatility
| 0RIS volatility | |
|---|---|
| 0RIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RIS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 17 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
| 0RIS fundamental statistics | |
|---|---|
| Market cap | NOK 56.45m |
| Earnings (TTM) | -NOK 449.26m |
| Revenue (TTM) | NOK 10.00m |
5.6x
P/S Ratio-0.1x
P/E RatioIs 0RIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RIS income statement (TTM) | |
|---|---|
| Revenue | NOK 10.00m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 10.00m |
| Other Expenses | NOK 459.26m |
| Earnings | -NOK 449.26m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 15, 2024
| Earnings per share (EPS) | -62.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,491.69% |
| Debt/Equity Ratio | -135.9% |
How did 0RIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/02 01:45 |
| End of Day Share Price | 2023/10/06 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Circio Holding ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Geir Holom | DNB Markets |
| Jonas Peciulis | Edison Investment Research |